ACB vs. GUD, OGI, CPH, CRDL, HLS, WEED, CRON, FRX, KSI, and EXE
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Knight Therapeutics (GUD), Organigram (OGI), Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Canopy Growth (WEED), Cronos Group (CRON), Fennec Pharmaceuticals (FRX), kneat.com (KSI), and Extendicare (EXE). These companies are all part of the "medical" sector.
Knight Therapeutics (TSE:GUD) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Aurora Cannabis has lower revenue, but higher earnings than Knight Therapeutics. Knight Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Knight Therapeutics presently has a consensus target price of C$6.58, indicating a potential upside of 14.89%. Aurora Cannabis has a consensus target price of C$2.26, indicating a potential downside of 75.36%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Aurora Cannabis.
Knight Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 2.83, meaning that its stock price is 183% more volatile than the S&P 500.
Aurora Cannabis received 418 more outperform votes than Knight Therapeutics when rated by MarketBeat users. However, 75.34% of users gave Knight Therapeutics an outperform vote while only 63.16% of users gave Aurora Cannabis an outperform vote.
13.7% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 7.0% of Aurora Cannabis shares are owned by institutional investors. 46.5% of Knight Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Aurora Cannabis had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Aurora Cannabis and 1 mentions for Knight Therapeutics. Aurora Cannabis' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.
Aurora Cannabis has a net margin of 151.71% compared to Aurora Cannabis' net margin of -5.13%. Aurora Cannabis' return on equity of -2.14% beat Knight Therapeutics' return on equity.
Summary
Knight Therapeutics beats Aurora Cannabis on 10 of the 17 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
